Invasive Lobular Carcinoma Breast Cancer: Symptoms, Treatment & Care
Table of Content
Invasive Lobular Carcinoma Breast Cancer
Invasive lobular carcinoma (ILC), also called infiltrating lobular carcinoma, is the second most common subtype of breast cancer, accounting for approximately 15% of all breast cancers. It starts in the lobules, the milk-producing glands of the breast, and extends into the surrounding breast tissue, classifying it as invasive lobular carcinoma breast cancer. Unlike ductal cancers that often form palpable lumps, ILC grows in a diffuse, single-file pattern, making it more difficult to detect on physical exam or imaging. Understanding what is invasive lobular carcinoma is important for timely diagnosis and effective treatment.
Symptoms and Signs of Invasive Lobular Carcinoma*
Invasive lobular carcinoma symptoms are often subtle or absent in early stages. Common signs of lobular carcinoma include:
- •Thickening or swellingIn part of the breast without a distinct lump
- •Changes in breast size or shape
- •Skin dimpling or puckering
- •Nipple inversion or discharge
- •Breast tenderness or discomfort
ILC may not produce a clear lump, which delays detection. Often, ILC is diagnosed through imaging, such as MRI, rather than physical symptoms.
Causes and Risk Factors of Invasive Lobular Carcinoma
While the exact invasive lobular carcinoma causes are not fully understood, known risk factors include:
- •Hormonal factorsLike prolonged estrogen exposure
- •Family history and genetic mutations(BRCA1/BRCA2, CDH1)
- •Postmenopausal status and age
- •Lifestyle factorsSuch as obesity and alcohol consumption
Awareness of these lobular carcinoma risk factors supports prevention and early screening.
Diagnosis and Staging of Invasive Lobular Carcinoma*
Diagnosis involves physical examination, mammography, breast MRI, ultrasound, and tissue biopsy. Due to its growth pattern, ILC can be difficult to detect with mammography alone, necessitating advanced imaging techniques.
Invasive lobular carcinoma stages range from stage 1 to stage 4:

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.
- •Stage 1 invasive lobular carcinomaSmall tumor confined to breast without lymph node involvement
- •Invasive lobular carcinoma stage 2Larger tumor or limited nodal spread
- •Stage 3 invasive lobular carcinomaExtensive local disease with significant lymph node involvement
- •Stage 4 invasive lobular carcinomaMetastasis to distant organs
Staging is critical to determining prognosis and guiding treatment.
Treatment Options for Invasive Lobular Carcinoma*
Invasive lobular carcinoma treatment is tailored to the cancer stage, receptor status, and patient health. Common treatments are:
- •Surgerylumpectomy or mastectomy, with sentinel lymph node biopsy
- Post-lumpectomy to lower risk of local recurrence
- As ILC usually expresses hormone receptors
- For advanced or high-risk tumors
- •Targeted YtherapiesYhttps://everhope.care/breast-cancer/therapy/targetedFor HER2-positive cancers
These follow established invasive lobular carcinoma treatment guidelines to optimize outcomes.
Prognosis and Survival Rate
The invasive lobular carcinoma prognosis is generally similar to ductal carcinoma when matched by stage. Early stages have good survival rates, but ILC may have a slightly higher chance of late recurrence, requiring long-term surveillance. The invasive lobular carcinoma survival rate improves significantly with appropriate, timely treatment.
Recurrence and Prevention
Invasive lobular carcinoma recurrence can occur years after initial treatment, highlighting the importance of ongoing follow-up. Lifestyle changes, genetic counseling, and regular screening play roles in prevention and early detection.
FAQs
Invasive Lobular Carcinoma
A breast cancer that begins in the milk-producing lobules and invades surrounding tissue.
Subtle breast thickening, nipple changes, skin dimpling, and sometimes no distinct lump.
Surgery, radiation, hormonal therapy, chemotherapy, targeted therapy based on tumor biology.
A larger tumor or limited lymph node involvement; prognosis is generally favorable with treatment.
